Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells

International Journal of Molecular Medicine

Volumn 28, Issue 4, 2011, Pages 527-534

  Choi, Baik Dong ^a   Jeong, Soon Jeong ^a   Guanlin, Wang ^a   Park, Jin Ju ^a   Lim, Do Seon ^b   Kim, Byung Hoon ^a   Cho, Yong Ick ^c   Kim, Chang Seok ^d   Jeong, Moon Jin ^a  

^a Chosun University   (South Korea)

^b Eulji University   (South Korea)

^c Photonics Technology Institute   (South Korea)

^d Bumin Busan Hospital   (South Korea)

Author keywords

Elk 1; Gastric cancer cell; Invasion; MMP 2; MMP 9; SLPI

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ELK 1;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; GENE EXPRESSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STOMACH CANCER;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; STOMACH NEOPLASMS;

EID: 79960783109     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.726     Document Type: Article

References (39)

1. Schwartz GK: Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol 23: 316-324, 1996.
2. Thompson RC and Ohlsson K: Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 83: 6692-6696, 1986. (Pubitemid 16002300)
3. Choi BD, Jeong SJ, Wang G, Kim HJ, Kim BO, Hwang HK, Lim DS, Kim SH and Jeong MJ: Temporal induction of secretory leukocyte protease inhibitor (SLPI) in odontoblasts by lipopolysaccharide and wound infection. J Endod 35: 997-1002, 2009.
4. McElvaney NG and Taggart CC: Chronic obstructive pulmonary disease: cellular and molecular mechanisms. Taylor and Francis. Barnes P (ed). Boca Raton, pp343-365, 2005.
5. Shugars DC and Wahl SM: The role of the oral environment in HIV-1 transmission. J Am Dent Assoc 129: 851-858, 1998. (Pubitemid 128459421)
6. Sallenave JM: Antimicrobial activity of antiproteinases. Biochem Soc Trans 30: 111-115, 2002.
7. Devoogdt N, Revets H, Ghassabeh GH and De Baetselier P: Secretory leukocyte protease inhibitor in cancer development. Ann NY Acad Sci 1028: 380-389, 2004. (Pubitemid 40361839)
8. Wang G, Lim DS, Choi BD, Park JJ, Jeong SJ, Kim JS, Kim JD, Park JS, Kim EK, Kim BH, Ham JH and Jeong MJ: Effect of secretory leukocyte protease inhibitor on migration and invasion of human KB oral carcinoma cells. Animal Cells and Systems (In press).
9. Liotta LA, Tryggvason K, Garbis S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980. (Pubitemid 10098769)
10. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002. (Pubitemid 37328786)
11. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE and Brooks PC: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154: 1069-1079, 2001. (Pubitemid 34286185)
12. Kim J, Yu W, Kovalski K and Ossowski L: Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94: 353-362, 1998. (Pubitemid 28376079)
13. Hua J and Muschel RJ: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56: 5279-5284, 1996. (Pubitemid 26383048)
14. Zhang Y, De Witt DL, McNeely TB, Wahl SM and Wahl LM: Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 99: 894-900, 1997. (Pubitemid 27123626)
15. Angelov N, Moutsopoulos N, Jeong MJ, Nares S, Ashcroft G and Wahl SM: Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitor. Thromb Haemost 92: 288-297, 2004. (Pubitemid 39172309)
16. Cheng WL, Wang CS, Huang YH, Liang Y, Lin PY, Hsueh C, Wu YC, Chen WJ, Yu CJ, Lin SR and Lin KH: Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer. Int J Cancer 123: 1787-1796, 2008.
17. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB and Verspaget HW: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74: 413-417, 1996. (Pubitemid 26254571)
18. Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH, Oh JH, Park HS, Yeo KS, Kang SH, Song SY, Kang YK, Bang YJ, Kim YH and Kim JP: Establishment and characterization of human gastric carcinoma cell lines. Int J Cancer 70: 443-449, 1997. (Pubitemid 27107273)
19. Choi BD, Lee SH, Jeong SJ, Jang HS, Kim BO, Lim DS, Park JC, Wang G and Jeong MJ: Increased protein of the secretory leukocyte protease inhibitor (SLPI) and expression of growth factors in NIH3T3 cells by LPS stimulation. Korean J Electron Microscopy 36: 165-172, 2006.
20. Morita M, Arakawa H and Nishimura S: Identification and cloning of a novel isoform of mouse secretory leukocyte protease inhibitor, mSLPI-β;, overexpressed in murine leukemias and a highly liver metastatic tumor, IMC-HA1 cells. Adv Enzyme Regul 33: 341-355, 1999.
21. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D and Viens P: Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64: 8558-8565, 2004. (Pubitemid 39552068)
22. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A and Suzumori K: Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 96: 516-519, 2005. (Pubitemid 40127158)
23. Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, Tournier JM and Birembaut P: Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer 72: 556-564, 1997. (Pubitemid 27356153)
24. Sakata K, Shigemasa K, Nagai N and Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17: 673-681, 2000.
25. Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, Kakeji Y and Sugimachi K: Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 17: 2253-2258, 1997. (Pubitemid 27320978)
26. Nomura H, Fujimoto N, Seiki M, Mai M and Okada Y: Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 69: 9-16, 1996. (Pubitemid 26083264)
27. Shaco-Levy R, Sharabi S, Piura B and Sion-Vardy N: MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium. Acta Obstet Gynecol Scand 87: 868-874, 2008.
28. Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T and Santala M: Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res 27: 2753-2758, 2007. (Pubitemid 47227993)
29. Ribeiro BF, Iglesias DP, Nascimento GJ, Galvão HC, Medeiros AM and Freitas RA: Immunoexpression of MMPs-1, -2, and -9 in ameloblastoma and odontogenic adenomatoid tumor. Oral Dis 15: 472-477, 2009.
30. Redondo P, Lloret P, Idoate M and Inoges S: Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 30: 541-545, 2005. (Pubitemid 41076024)
31. Sampieri CL, De la Peña S, Ochoa-Lara M, Zenteno-Cuevas R and León-Córdoba K: Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis. World J Gastroenterol 16: 1500-1505, 2010.
32. Väisänen AH, Kallioinen M and Turpeenniemi-Hujanen T: Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol 39: 377-385, 2008.
33. Murata E, Sharmin S, Shiota H, Shiota M, Yano M and Kido H: The effect of topically applied secretory leukocyte protease inhibitor on the eosinophil response in the late phase of allergic conjunctivitis. Curr Eye Res 26: 271-276, 2003. (Pubitemid 36876228)
34. Sehnert B, Cavcic A, Böhm B, Kalden JR, Nandakumar KS, Holmdahl R and Burkhardt H: Antileukoproteinase: modulation of neutrophil function and therapeutic effects on anti-type II collagen antibody-induced arthritis. Arthritis Rheum 50: 2347-2359, 2004. (Pubitemid 38924415)
35. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM and Fodstad O: High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3: 1623-1628, 1997. (Pubitemid 27431572)
36. Qu MY, Luo BL, Chen HM, Feng JT and Gu QH: Effects of secretory leukocyte protease inhibitor on expression of inflammation mediators in normal human bronchial epithelial cells induced by cigarette smoke extract. Zhonghua Jie He He Hu Xi Za Zhi 31: 352-355, 2008.
37. Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K and Eguchi K: Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 35: 1117-1124, 2002. (Pubitemid 34454008)
38. Hsieh HL, Wu CY and Yang CM: Bradykinin induces matrix metalloproteinase-9 expression and cell migration through a PKC-delta-dependent ERK/Elk-1 pathway in astrocytes. Glia 56: 619-632, 2008.
39. Mahmoodzadeh S, Dworatzek E, Fritschka S, Pham TH and Regitz-Zagrosek V: 17beta-estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts. Cardiovasc Res 85: 719-728, 2010.